DiscoverCheckpoint NOWEpisode 15: Neuro-toxicities from Immune checkpoint Blockade: Rare and complex (Part 1)
Episode 15: Neuro-toxicities from Immune checkpoint Blockade: Rare and complex (Part 1)

Episode 15: Neuro-toxicities from Immune checkpoint Blockade: Rare and complex (Part 1)

Update: 2021-07-13
Share

Description

Learn from the experts about immune mediated neurological toxicities. Join our hosts Dr. Afreen Shariff and Dr. Tian Zhang as they discuss with guest expert and Neurologist Dr. Andrew Mammen. 


Andrew Mammen, M.D., Ph.D., joined NIAMS as Muscle Disease Unit Leader in the Laboratory of Muscle Stem Cells and Gene Regulation in 2014. He obtained his medical degree and Ph.D. in neuroscience at Johns Hopkins in 2000, where he subsequently completed his medicine internship, neurology residency, and neuromuscular fellowship. Prior to his appointment at NIH, he was Associate Professor of Neurology and Medicine at the Johns Hopkins University School of Medicine. He co-founded the Johns Hopkins Myositis Center in 2007, where he continues to see myositis patients as an adjunct faculty member. Dr. Mammen and his colleagues at Hopkins discovered a novel form of autoimmune myopathy associated with statin use and autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. In addition to clinical studies involving myositis patients, his current laboratory research interests include defining pathogenic mechanisms in the various forms of autoimmune myopathy and understanding the role of myositis autoantigens in muscle regeneration.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Episode 15: Neuro-toxicities from Immune checkpoint Blockade: Rare and complex (Part 1)

Episode 15: Neuro-toxicities from Immune checkpoint Blockade: Rare and complex (Part 1)

Afreen Shariff